Your Global Leader in Stem Cell Market Research
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Fight the signs of premature aging with these stem cell skin care beauty products. A lot of companies claim to incorporate the benefits of plant and human stem cells, as well as components secreted by them, into the best stem cell beauty products on the market.
Below, we present what appears (based on company claims) to be ten of the best products available today. [Read more…]
CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world. By the end of 2020, CryoHoldco will be seven times larger than any other stem cell bank in Latin America and will have 275,000 stem cell units in storage.
The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has also been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
The global cord blood banking industry has been rapidly maturing in recent years. In part, this has been caused by changes in processing, storage, and transplantation technologies. These changes require executives and industry decision-makers to have a firm understanding of emerging trends.
One of the most notable cord blood industry trends has been a diversification of services. Put simply, cord blood banks are becoming diversified stem cell biobanks. [Read more…]
HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
